Fas and Fas ligand expression in tumor cells and in vascular smooth-muscle cells of colonic and renal carcinomas.
CD95/APO-1 ligand (FasL) is implicated in the maintenance of immune privileged sites by inducing apoptosis of activated infiltrating T lymphocytes. Therefore, progressive tumors might express high levels of FasL and develop as immune privileged sites. In this study, we investigated the expression of FasL and CD95/APO-1 (Fas, the FasL-receptor) in vitro in rat adenocarcinoma cell lines and the localization in situ in normal human kidney and colon and in their adenocarcinomas. The rat cell line PROb (a progressive tumor in vivo) expressed a higher level of FasL than the sister cell line REGb (a regressive tumor in vivo), as detected by flow cytometry. The 2 cell lines expressed the same level of Fas, but were resistant to FasL-induced apoptosis. In human tissue, both kidney and colon extracts expressed FasL by Western blot. Further investigations, using immunohistochemical staining of paraffin sections, showed that normal colon mucosa expressed Fas and FasL in crypt epithelial cells in the subnuclear compartment. Normal kidney showed Fas and FasL labeling mostly restricted to epithelial cells of proximal tubules and Henlé's loop, showing that this expression is not uniform throughout the organ. Smooth-muscle cells of muscularis propria and blood vessels in and around the tumors were also intensely but more uniformly labeled. In colon-cancer cells, FasL expression remained strong, whereas Fas expression was significantly reduced. A similar reduction in Fas expression was noted in renal-cancer cells. Tumor-infiltrating immune cells of the macrophage lineage do not express FasL. Our results show that smooth-muscle cells of muscularis propria and blood vessels are able to express FasL and to a slight extent Fas. In normal epithelial cells of colon and kidney, Fas and FasL are often co-expressed. The reduced expression of Fas in corresponding cancer cells in combination with the ability to express FasL might facilitate immune escape.
D000230:Adenocarcinoma / Q000098:blood supply / Q000378:metabolism*; D000818:Animals; D015153:Blotting, Western; D002292:Carcinoma, Renal Cell / Q000098:blood supply / Q000378:metabolism*; D003106:Colon / Q000098:blood supply / Q000378:metabolism; D003110:Colonic Neoplasms / Q000098:blood supply / Q000378:metabolism*; D053222:Fas Ligand Protein; D005434:Flow Cytometry; D006801:Humans; D007150:Immunohistochemistry; D007413:Intestinal Mucosa / Q000098:blood supply / Q000378:metabolism; D007668:Kidney / Q000098:blood supply / Q000378:metabolism; D007680:Kidney Neoplasms / Q000098:blood supply / Q000378:metabolism*; D008562:Membrane Glycoproteins / Q000096:biosynthesis*; D009131:Muscle, Smooth, Vascular / Q000098:blood supply / Q000378:metabolism*; D051381:Rats; D014407:Tumor Cells, Cultured; D019014:fas Receptor / Q000096:biosynthesis*